ENSG Healthcare

The Ensign Group, Inc.

$182.21+1.76%

Price as of close on Nov 3, 2026 · Financials updated Oct 8, 2026

Basics

Sector: Healthcare
Industry: Medical Care Facilities
Country: United States
Market cap: 10.6B USD
Enterprise value: 10.1B USD
Full-time employees: 46,000

Overall health

Strength: its shares are priced lower than most peers relative to what it earnspriced lower than peers for its earnings
Drawback: less short-term liquidity (current ratio 1.21 vs a peer median of 2.59)less liquidity (current ratio 1.21 vs peers 2.59)
About average: risk (debt, liquidity and share-price swings)risk

Ranks #266 of 1,157 healthcare companies (top 23%)

See how it ranks against its peers

Worth knowing

Stock pay outran buybacks. Stock-based pay expense $115M vs $20M spent repurchasing shares over the 3 fiscal years to 2025. Shares outstanding changed +4.7% from December 2022 to July 2026.
Over three fiscal years Ensign recorded $115M of stock-based pay expense and spent $20M repurchasing shares (repurchases can include shares withheld to cover employees' taxes). Repurchases were smaller than the stock pay, so they did little to offset new employee shares.Over three fiscal years Ensign recorded $115M of stock-based pay expense and spent $20M repurchasing shares. Repurchases were smaller than the stock pay, so they did little to offset new employee shares.
Sales growing faster than profits. Since 2022: revenue +67%, operating profit +43%.
Since 2022, Ensign's revenue changed +67% but operating profit only +43%: costs are rising faster than sales.
Annual revenue rose 5 years in a row. Fiscal-year revenue rose from $2.4B in 2020 to $5.1B in 2025.
Ensign's fiscal-year revenue rose in each of the five years to 2025, from $2.4B to $5.1B.
Profit is backed by cash. Free cash flow is 111% of reported profit.
Ensign's free cash flow is 111% of its reported profit, so its earnings are turning into cash it can reinvest, pay out or use to reduce debt.

StockQuotient Score

64/ 100

Oct 5 64 → Nov 4 64

Valuation

Is the price right?

61/100

Moderate▼ 2 since Oct 27 close

3/3 inputs reported · High confidence

Since last quarter: No major changeValuation also moves with the share price every day.

Why it changed since the Oct 27, 2026 close: Score 63 → 61

Share price +7.5%-2

Each step re-scores the company against its peers as they were on Oct 28, 2026; the parts add up to the change. Price effects on EBITDA yield are approximate.

Why

Stronger than most peers on:

▲ Earnings yield

Compare with peers

Behind the score

Sector-normalized EBITDA, earnings, and free cash flow yields.

Earnings yield3.6%

SEC filings · 12 months to Jun 2026Reported value30% base weight · Z-score 1.41Sector median: 0.0148 · MAD: 0.0148

EBITDA yield5.6%

SEC filings · 12 months to Jun 2026Reported value50% base weight · Z-score 0.40Sector median: 0.0401 · MAD: 0.0401

Free cash flow yield3.9%

Yahoo Finance fallback · SEC cash flow or share count unavailable · trailing 12 months · operating cash flow − capital spendingReported value20% base weight · Z-score 0.00Sector median: 0.0000 · MAD: 0.0000

Other data (not scored)

Book yield23.0%

SEC filings · latest balance sheetReported valueInformational · 0% composite weightSector median: 0.3716 · MAD: 0.2313

Growth

Is it growing?

70/100

Moderate

3/3 inputs reported · High confidence

Since last quarter: ▲ Stronger

12-month revenue up 4.0%

Why

Stronger than most peers on:

▲ 3-yr revenue
▲ Revenue growth

Compare with peers

Behind the score

Revenue and earnings-per-share growth over one year, and revenue growth over three years.

Earnings per share growth16.1%

SEC filings · 12 months to Jun 2026Reported value33% base weight · Z-score 0.21Sector median: 0.0976 · MAD: 0.2991

3-year revenue growth17.4%

SEC filings · 3 years to Jun 2026Reported value33% base weight · Z-score 1.38Sector median: 0.0584 · MAD: 0.0840

Revenue growth18.9%

SEC filings · 12 months to Jun 2026Reported value33% base weight · Z-score 1.31Sector median: 0.0609 · MAD: 0.0974

Profitability

Does it earn well?

73/100

Moderate

3/3 inputs reported · High confidence

Since last quarter: No major change

Why

Stronger than most peers on:

▲ ROIC
▲ ROA

Compare with peers

Behind the score

Return on invested capital, operating margin, and return on assets.

Operating margin8.5%

SEC filings · 12 months to Jun 2026Reported value33% base weight · Z-score 0.12Sector median: 0.0706 · MAD: 0.1217

Return on assets6.6%

SEC filings · 12 months to Jun 2026Reported value33% base weight · Z-score 0.92Sector median: 0.0166 · MAD: 0.0537

Return on invested capital15.9%

SEC filings · 12 months to Jun 2026Reported value33% base weight · Z-score 1.12Sector median: 0.0471 · MAD: 0.1004

Other data (not scored)

Gross margin20.7%

SEC filings · 12 months to Jun 2026Reported valueInformational · 0% composite weightSector median: 0.4697 · MAD: 0.2310

Return on equity15.5%

SEC filings · 12 months to Jun 2026Reported valueInformational · 0% composite weightSector median: 0.0330 · MAD: 0.1225

Risk

Debt, liquidity, price swings

Moderate

Moderate relative risk

3/3 inputs reported · High confidence

Since last quarter: No major change

Why it changed since the Oct 27, 2026 close: Safety percentile 50 → 51

Peer companies moved+1

Each step re-scores the company against its peers as they were on Oct 28, 2026; the parts add up to the change. Price effects on EBITDA yield are approximate.

Why

Mixed versus peers:

▲ Debt / equity
▼ Current ratio

Compare with peers

Behind the score

Relative to sector peers: 0 = lower relative risk · 1 = moderate · 2 = higher. Based on leverage, beta and liquidity.

Beta0.66

Yahoo Finance · 5-year monthly beta vs the marketReported value33% base weight · Z-score -0.10Sector median: 0.6250 · MAD: 0.3380

Current ratio1.21×

SEC filings · latest balance sheetReported value33% base weight · Z-score -0.99Sector median: 2.5860 · MAD: 1.3850

Debt / equity0.06×

SEC filings · latest balance sheetReported value33% base weight · Z-score 0.81Sector median: 0.2215 · MAD: 0.2039

Valuation, growth and profitability scores: higher is better. Risk: 0 is lower, 2 is higher. Risk is a relative proxy, not a bankruptcy probability. Scores depend on available sector peers.

Questions investors ask about Ensign

Is Ensign getting weaker?: Its latest SEC filing (Jul 27, 2026) showed no major changes. Its overall score is unchanged at 64/100 since Oct 28, 2026.
How is Ensign valued vs its peers?: Priced lower than most peers relative to what it earns. Valuation scores 61/100 against 1,393 healthcare peers. Earnings yield 3.6% vs a peer median of 1.5% (stronger than 67% of peers).Earnings yield 3.6% vs peers 1.5% (stronger than 67% of peers).
Is Ensign growing?: Yes, faster than most of its peers. Growth scores 70/100 against 1,393 healthcare peers. 3-year revenue growth 17.4% vs a peer median of 5.8% (stronger than 77% of peers).3-year revenue growth 17.4% vs peers 5.8% (stronger than 77% of peers).
How profitable is Ensign?: More profitable than most of its peers. Profitability scores 73/100 against 1,393 healthcare peers. Return on invested capital 15.9% vs a peer median of 4.7% (stronger than 81% of peers).Return on invested capital 15.9% vs peers 4.7% (stronger than 81% of peers).
How risky is Ensign?: Moderate risk relative to 1,393 healthcare peers, judged on debt, liquidity and share-price swings. Debt / equity 0.06× vs a peer median of 0.22× (stronger than 74% of peers).Debt / equity 0.06× vs peers 0.22× (stronger than 74% of peers). Current ratio 1.21× vs a peer median of 2.59× (weaker than 84% of peers).Current ratio 1.21× vs peers 2.59× (weaker than 84% of peers). A relative measure, not a bankruptcy probability.

Latest filing: what changed

Quarter ended Jun 30, 2026 · filed Jul 27, 2026 · compared with the quarter ended Mar 31, 2026

No major changes

	Previous quarter	Latest quarter	Change
Revenue (12 months)	5.3B USD	5.5B USD	+4.0%
Net income (12 months)	363.4M USD	378.7M USD	+4.2%
Operating margin	8.5%	8.5%	+0.0 pts
Debt	140.8M USD	139.7M USD	−0.7%
Cash	539.5M USD	262.3M USD	−51.4%
Shares outstanding	58.4M	58.3M	−0.3%

From the company’s own SEC filings, as filed. Twelve-month figures roll forward one quarter at a time.

Industry valuation context

Industry: Medical Care Facilities · 27 companies

Valuations in Medical Care Facilities are within their usual range since Jun 2017.

39% of months since Jun 2017 were valued lower than now.
28% of companies are in the most expensive fifth of their own price-to-sales history.
Median price-to-sales is −61% vs the whole market, against a usual −56%.

Jun 2017Shaded: most expensive fifth of its range2026

Financials

Fiscal years from SEC annual filings · change vs the prior year

Key ratios	FY 2021	FY 2022	FY 2023	FY 2024	FY 2025	Change
Gross margin	23.1%	22.2%	21.1%	20.7%	20.5%	▼ 0.2 pts
Operating margin	9.9%	9.8%	6.8%	8.4%	8.4%	▼ 0.0 pts
Net margin	7.4%	7.4%	5.6%	7.0%	6.8%	▼ 0.2 pts
Return on assets (ROA)	6.8%	6.5%	5.0%	6.4%	6.3%	▼ 0.1 pts
Return on equity (ROE)	19.1%	18.0%	14.0%	16.2%	15.4%	▼ 0.8 pts
Current ratio	1.22×	1.34×	1.42×	1.56×	1.42×	▼ 8.6%
Debt to equity	0.16×	0.13×	0.10×	0.08×	0.06×	▼ 20%
Interest coverage	38.03×	33.24×	31.58×	43.24×	53.24×	▲ 23%

ENSG price history

Price history is added with the daily price update and will appear after the next one.

Similar companies

Sector leaderboards

BB Biotech AGBBZA.DE100/ 100

Arbutus Biopharma CorporationABUS97/ 100

Q32 Bio Inc.QTTB97/ 100

Bringing the fundamentals into focus…

Overall health

Strength: its shares are priced lower than most peers relative to what it earnspriced lower than peers for its earnings

Drawback: less short-term liquidity (current ratio 1.21 vs a peer median of 2.59)less liquidity (current ratio 1.21 vs peers 2.59)

About average: risk (debt, liquidity and share-price swings)risk

Ranks #266 of 1,157 healthcare companies (top 23%)

See how it ranks against its peers

Worth knowing

Stock pay outran buybacks. Stock-based pay expense $115M vs $20M spent repurchasing shares over the 3 fiscal years to 2025. Shares outstanding changed +4.7% from December 2022 to July 2026.

Over three fiscal years Ensign recorded $115M of stock-based pay expense and spent $20M repurchasing shares (repurchases can include shares withheld to cover employees' taxes). Repurchases were smaller than the stock pay, so they did little to offset new employee shares.Over three fiscal years Ensign recorded $115M of stock-based pay expense and spent $20M repurchasing shares. Repurchases were smaller than the stock pay, so they did little to offset new employee shares.

Sales growing faster than profits. Since 2022: revenue +67%, operating profit +43%.

Since 2022, Ensign's revenue changed +67% but operating profit only +43%: costs are rising faster than sales.

Annual revenue rose 5 years in a row. Fiscal-year revenue rose from $2.4B in 2020 to $5.1B in 2025.

Ensign's fiscal-year revenue rose in each of the five years to 2025, from $2.4B to $5.1B.

Profit is backed by cash. Free cash flow is 111% of reported profit.

Ensign's free cash flow is 111% of its reported profit, so its earnings are turning into cash it can reinvest, pay out or use to reduce debt.

Questions investors ask about Ensign

Is Ensign getting weaker?

Its latest SEC filing (Jul 27, 2026) showed no major changes. Its overall score is unchanged at 64/100 since Oct 28, 2026.

How is Ensign valued vs its peers?

Priced lower than most peers relative to what it earns. Valuation scores 61/100 against 1,393 healthcare peers. Earnings yield 3.6% vs a peer median of 1.5% (stronger than 67% of peers).Earnings yield 3.6% vs peers 1.5% (stronger than 67% of peers).

Is Ensign growing?

Yes, faster than most of its peers. Growth scores 70/100 against 1,393 healthcare peers. 3-year revenue growth 17.4% vs a peer median of 5.8% (stronger than 77% of peers).3-year revenue growth 17.4% vs peers 5.8% (stronger than 77% of peers).

How profitable is Ensign?

More profitable than most of its peers. Profitability scores 73/100 against 1,393 healthcare peers. Return on invested capital 15.9% vs a peer median of 4.7% (stronger than 81% of peers).Return on invested capital 15.9% vs peers 4.7% (stronger than 81% of peers).

How risky is Ensign?

Moderate risk relative to 1,393 healthcare peers, judged on debt, liquidity and share-price swings. Debt / equity 0.06× vs a peer median of 0.22× (stronger than 74% of peers).Debt / equity 0.06× vs peers 0.22× (stronger than 74% of peers). Current ratio 1.21× vs a peer median of 2.59× (weaker than 84% of peers).Current ratio 1.21× vs peers 2.59× (weaker than 84% of peers). A relative measure, not a bankruptcy probability.

Previous quarter

Latest quarter

Change

Revenue (12 months)

5.3B USD

5.5B USD

+4.0%

Net income (12 months)

363.4M USD

378.7M USD

+4.2%

Operating margin

8.5%

8.5%

+0.0 pts

Debt

140.8M USD

139.7M USD

−0.7%

Cash

539.5M USD

262.3M USD

−51.4%

Shares outstanding

58.4M

58.3M

−0.3%

Key ratios

FY 2021

FY 2022

FY 2023

FY 2024

FY 2025

Change

Gross margin

23.1%

22.2%

21.1%

20.7%

20.5%

▼ 0.2 pts

Operating margin

9.9%

9.8%

6.8%

8.4%

▼ 0.0 pts

Net margin

7.4%

5.6%

7.0%

6.8%

▼ 0.2 pts

Return on assets (ROA)

6.8%

6.5%

5.0%

6.4%

6.3%

▼ 0.1 pts

Return on equity (ROE)

19.1%

18.0%

14.0%

16.2%

15.4%

▼ 0.8 pts

Current ratio

1.22×

1.34×

1.42×

1.56×

1.42×

▼ 8.6%

Debt to equity

0.16×

0.13×

0.10×

0.08×

0.06×

▼ 20%

Interest coverage

38.03×

33.24×

31.58×

43.24×

53.24×

▲ 23%